Evidence map›Paper›PMID 35302478›Full record

ArticleBlood transfusion = Trasfusione del sangue2022

Anti-SARS-CoV-2 vaccination does not influence anticoagulation levels in stable long-term warfarin treatment.

Elena Lotti, Alessandro Masi, Chiara Cappugi, Alessandra Fanelli, Lucia Mannini, Rossella Marcucci, Daniela Poli

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. COVID-19 vaccination, anticoagulation level and warfarin treatment.Blood transfusion = Trasfusione del sangue · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Elena LottiThrombosis Center University Hospital Careggi, Florence, Italy.
Alessandro MasiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Chiara CappugiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Alessandra FanelliGeneral Laboratory, University Hospital Careggi, Florence, Italy.
Lucia ManniniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Rossella MarcucciDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Daniela PoliThrombosis Center University Hospital Careggi, Florence, Italy.
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, administration of the currently available vaccines has mostly been recommended for subjects at high risk, including elderly populations on long-term oral anticoagulation therapy (OAT) with warfarin. However, there is no clear evidence of the stability of the International Normalised Ratio (INR) after vaccine administration in those subjects on long-term OAT. The present study aimed to investigate the effects of COVID-19 vaccination on anticoagulation levels in patients on long-term OAT. MATERIALS AND

methodsINR values of patients on long-term OAT who had undergone anti-SARS-CoV-2 vaccination from January to June 2021 were monitored for a total of 90 days follow-up after the first vaccination dose. These were then compared with INR values before vaccination. The second dose, when required, was administered during follow-up. Inclusion criterion was stable long-term INR for at least 6 months before vaccination. Exclusion criteria were recent surgery, intercurrent diseases, or treatment with medication that could compromise findings in the 3 months before vaccination and during follow-up.

resultsNo differences were observed in the anticoagulation levels before and after COVID-19 vaccination in any of the patients studied: mean INR values were 2.39 (range 2.20-2.63) before vaccination and 2.40 (range 2.16-2.76) after vaccination (p=0.5). There was no difference in anticoagulation levels in relation to age, sex, indication for OAT, or type of vaccine (p>0.5). No bleeding or thrombotic complications were documented during follow-up. DISCUSSION: These are the first data to be reported on anticoagulation levels in patients on stable OAT after COVID-19 vaccination. No influence on the quality of OAT was detected after the vaccination; no bleeding or thrombotic complications were recorded in the follow-up. No difference between the four available COVID vaccines was found. Dose adjustment was only required in a few cases, thus confirming the stability of anticoagulation levels.

Indexed as

COVID-19WarfarinAdministration, OralAgedAnticoagulantsCOVID-19 VaccinesHemorrhageHumansInternational Normalized RatioSARS-CoV-2VaccinationAnticoagulantsCOVID-19 VaccinesWarfarin

Identifiers

PMID35302478
PMCPMC9480967
OpenAlexW4220792409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.